Nonalcoholic Fatty Liver Disease
Conditions
Brief summary
The aim of the present study is to assess, by using a simple algorithm combining FIB-4 and Fibroscan, the prevalence of NASH with advanced fibrosis in outpatients followed in various hospital specialty clinics other than hepato/gastroenterology and to examine risk factors associated with this condition. The prevalence of NASH will be investigated among 6 cohorts of outpatients followed in different hospital specialty clinics at Hôpitaux Universitaires de Strasbourg.
Interventions
None listed
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age ≥ 18 years * outpatients followed at specialty clinics in HUS and at risk of NAFLD: with at least one metabolic risk factor (overweight, diabetes mellitus, hypertension, hypertriglyceridemia) and/or elevated transaminases and/or liver steatosis on US. * endocrinology cohort : type 2 diabetes patients * infectious disease cohort : HIV positive patients * rheumatology cohort : patients with psoriasis, gout or rheumatoid arthritis * nephrology cohort : patients with chronic kidney disease such as diabetic nephropathy or hypertensive nephropathy, including those receiving hemodialysis. * cardiology cohorts: patients with history of angina, myocardial infarction, stroke or arteritis of lower limbs. * internal medicine cohort: patients with auto immune systemic diseases such as lupus, sclerosis or rheumatoid arthritis. * subjects who have given their informed consent * Subjects affiliated to a social security system
Exclusion criteria
* alcohol consumption \> 30g/d in male or \> 20g/d in female in the past 6 months * history of chronic viral hepatitis * history of liver auto immune disease, genetic hemochromatosis, Wilson disease * biliary disease, bile duct obstruction * drug-induced liver injury * secondary liver cancer or other active cancer * organ graft * use of medications associated with secondary NAFLD (corticosteroids, tamoxifen, amiodarone, methotrexate). * congestive heart failure * AIDS * pregnancy, breastfeeding * no information could be given to the patient (subject faces emergency situation, comprehension difficulties, etc.) * patient under guardianship * patients under judicial protection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimated prevalence of NASH with advanced fibrosis among several hospital specialty clinics | 3 months | To assess the estimated prevalence of NASH , calcul of the FIB4 |
Countries
France
Outcome results
None listed